Invention Grant
- Patent Title: Tetrameric cytokines with improved biological activity
-
Application No.: US15291490Application Date: 2016-10-12
-
Publication No.: US09931413B2Publication Date: 2018-04-03
- Inventor: Chien-Hsing Chang , David M. Goldenberg , Edmund A. Rossi
- Applicant: IBC Pharmaceuticals, Inc.
- Applicant Address: US NJ Morris Plains
- Assignee: IBC Pharmaceuticals, Inc.
- Current Assignee: IBC Pharmaceuticals, Inc.
- Current Assignee Address: US NJ Morris Plains
- Agent Richard A. Nakashima
- Main IPC: A61K47/48
- IPC: A61K47/48 ; C07K16/28 ; C07K14/56 ; C07K14/54 ; C07K14/52 ; C07K16/00 ; C07K14/535 ; C07K14/505 ; C12N9/12 ; A61K39/00 ; A61K38/00

Abstract:
The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers that bind to the AD moieties, resulting in a 2:1 ratio of DDD to AD. The cytokine-MAb complex exhibits improved pharmacokinetics, with a significantly longer serum half-life than either naked cytokine or PEGylated cytokine. The cytokine-MAb complex also exhibits significantly improved in vitro and in vivo efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or cytokine-MAb DNL complexes incorporating an irrelevant antibody. In more preferred embodiment the cytokine is G-CSF, erythropoietin or INF-α2b.
Public/Granted literature
- US20170056516A1 Tetrameric Cytokines with Improved Biological Activity Public/Granted day:2017-03-02
Information query